Name: 抗菌スクリーニングモデルとしてのGalleria mellonella (動画) | JoVE Journal
Uploaded: 2024-10-11T14:20:00.000+00:00
Duration: 6 min 19 s
Description: 学ぶGalleria mellonella感染モデルを用いた前臨床抗菌薬評価の標準化手法。トブラマイシンの最適用量と治療タイミングによる生存率向上を検証し、慢性呼吸器感染症治療薬開発の信頼性向上に貢献する。

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

<meta charset="utf8"></head><body>前臨床抗菌試験のための標準化された Galleria mellonella モデル

<ol><li>Menard, G., Rouillon, A., Cattoir, V., Donnio, P. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella+as+a+suitable+model+of+bacterial+infection%3A+Past%2C+present+and+future%5BTitle%5D)+AND+%22Front+Cell+Infect+Microbiol%22%5BJournal%5D)">Galleria mellonella as a suitable model of bacterial infection: Past, present and future.</a> Front Cell Infect Microbiol. 11, 782733(2021).</li>
<li>Piatek, M., Sheehan, G., Kavanagh, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella%3A+The+versatile+host+for+drug+discovery%2C+in+vivo+toxicity+testing+and+characterizing+host-pathogen+interactions%5BTitle%5D)+AND+%22Antibiotics%22%5BJournal%5D)">Galleria mellonella: The versatile host for drug discovery, in vivo toxicity testing and characterizing host-pathogen interactions.</a> Antibiotics. 10 (12), 1545(2021).</li>
<li>Miethke, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Towards+the+sustainable+discovery+and+development+of+new+antibiotics%5BTitle%5D)+AND+%22Nat+Rev+Chem%22%5BJournal%5D)">Towards the sustainable discovery and development of new antibiotics.</a> Nat Rev Chem. 5 (10), 726-749 (2021).</li>
<li>Seyhan, A. A. Lost in translation: The valley of death across preclinical and clinical divide - identification of problems and overcoming obstacles. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aSeyhan%2C+AA+%22Transl+Med+Commun%22">Transl Med Commun</a>. 4 (1), (2019).</li>
<li>Firacative, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Rearing+and+maintenance+of+Galleria+mellonella+and+its+application+to+study+fungal+virulence%5BTitle%5D)+AND+%22J+Fungus%22%5BJournal%5D)">Rearing and maintenance of Galleria mellonella and its application to study fungal virulence.</a> J Fungus. 6 (3), 130(2020).</li>
<li>Pereira, M. F., Rossi, C. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Overview+of+rearing+and+testing+conditions+and+a+guide+for+optimizing+Galleria+mellonella+breeding+and+use+in+the+laboratory+for+scientific+purposes%5BTitle%5D)+AND+%22APMIS%22%5BJournal%5D)">Overview of rearing and testing conditions and a guide for optimizing Galleria mellonella breeding and use in the laboratory for scientific purposes.</a> APMIS. 128 (12), 607-620 (2020).</li>
<li>Jorjão, A. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((From+moths+to+caterpillars%3A+Ideal+conditions+for+Galleria+mellonella+rearing+for+in+vivo+microbiological+studies%5BTitle%5D)+AND+%22Virulence%22%5BJournal%5D)">From moths to caterpillars: Ideal conditions for Galleria mellonella rearing for in vivo microbiological studies.</a> Virulence. 9 (1), 383-389 (2018).</li>
<li>Tsai, C. J. -Y., Loh, J. M. S., Proft, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella+infection+models+for+the+study+of+bacterial+diseases+and+for+antimicrobial+drug+testing%5BTitle%5D)+AND+%22Virulence%22%5BJournal%5D)">Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing.</a> Virulence. 7 (3), 214-229 (2016).</li>
<li>Gallorini, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunophenotyping+of+hemocytes+from+infected+Galleria+mellonella+larvae+as+an+innovative+tool+for+immune+profiling%2C+infection+studies+and+drug+screening%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Immunophenotyping of hemocytes from infected Galleria mellonella larvae as an innovative tool for immune profiling, infection studies and drug screening.</a> Sci Rep. 14, 759(2024).</li>
<li>Smith, F. Q., Casadevall, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fungal+immunity+and+pathogenesis+in+mammals+versus+the+invertebrate+model+organism+Galleria+mellonella%5BTitle%5D)+AND+%22Pathog+Dis%22%5BJournal%5D)">Fungal immunity and pathogenesis in mammals versus the invertebrate model organism Galleria mellonella.</a> Pathog Dis. 79 (3), ftab013(2021).</li>
<li>Sugumaran, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparative+biochemistry+of+eumelanogenesis+and+the+protective+roles+of+phenoloxidase+and+melanin+in+insects%5BTitle%5D)+AND+%22Pigment+Cell+Res%22%5BJournal%5D)">Comparative biochemistry of eumelanogenesis and the protective roles of phenoloxidase and melanin in insects.</a> Pigment Cell Res. 15 (1), 2-9 (2002).</li>
<li>Sheehan, G., Garvey, A., Croke, M., Kavanagh, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Innate+humoral+immune+defences+in+mammals+and+insects%3A+The+same%2C+with+differences%5BTitle%5D)+AND+%22Virulence%22%5BJournal%5D)">Innate humoral immune defences in mammals and insects: The same, with differences.</a> Virulence. 9, 1625-1639 (2018).</li>
<li>Wright, C. L., Kavanagh, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella+as+a+novel+in+vivo+model+to+screen+natural+product-derived+modulators+of+innate+immunity%5BTitle%5D)+AND+%22Appl+Sci%22%5BJournal%5D)">Galleria mellonella as a novel in vivo model to screen natural product-derived modulators of innate immunity.</a> Appl Sci. 12 (13), 6587(2022).</li>
<li>Newton, S. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+the+invertebrate+Galleria+mellonella+as+an+infection+model+to+study+the+Mycobacterium+tuberculosis+complex%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Use of the invertebrate Galleria mellonella as an infection model to study the Mycobacterium tuberculosis complex.</a> J Vis Exp. (148), e59703(2019).</li>
<li>Frankel, G., Collins, J. W., Schroeder, G. N., Harding, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+Galleria+mellonella+as+a+model+organism+to+study+Legionella+pneumophila+infection%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Use of Galleria mellonella as a model organism to study Legionella pneumophila infection.</a> J Vis Exp. (81), e50964(2013).</li>
<li>Romera, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+Galleria+mellonella+infection+model+as+a+system+to+investigate+the+virulence+of+Candida+auris+strains%5BTitle%5D)+AND+%22Pathog+Dis%22%5BJournal%5D)">The Galleria mellonella infection model as a system to investigate the virulence of Candida auris strains.</a> Pathog Dis. 78 (9), ftaa067(2020).</li>
<li>Kwadha, C. A., Ong'amo, G. O., Ndegwa, P. N., Raina, S. K., Fombong, A. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+biology+and+control+of+the+greater+wax+moth%2C+Galleria+mellonella%5BTitle%5D)+AND+%22Insects%22%5BJournal%5D)">The biology and control of the greater wax moth, Galleria mellonella.</a> Insects. 8 (2), 61(2017).</li>
<li>Miles, A. A., Misra, S. S., Irwin, J. O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+estimation+of+the+bactericidal+power+of+the+blood%5BTitle%5D)+AND+%22J+Hyg%22%5BJournal%5D)">The estimation of the bactericidal power of the blood.</a> J Hyg. 38, 732-749 (1938).</li>
<li>Ignasiak, K., Maxwell, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella+%28greater+wax+moth%29+larvae+as+a+model+for+antibiotic+susceptibility+testing+and+acute+toxicity+trials%5BTitle%5D)+AND+%22BMC+Res+Notes%22%5BJournal%5D)">Galleria mellonella (greater wax moth) larvae as a model for antibiotic susceptibility testing and acute toxicity trials.</a> BMC Res Notes. 10 (1), 428(2017).</li>
<li>Hesketh-Best, P. J., Mouritzen, M. V., Shandley-Edwards, K., Billington, R. A., Upton, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Galleria+mellonella+larvae+exhibit+a+weight-dependent+lethal+median+dose+when+infected+with+methicillin-resistant+Staphylococcus+aureus%5BTitle%5D)+AND+%22Pathog+Dis%22%5BJournal%5D)">Galleria mellonella larvae exhibit a weight-dependent lethal median dose when infected with methicillin-resistant Staphylococcus aureus.</a> Pathog Dis. 79 (2), ftab003(2021).</li>
<li>Mahenthiralingam, E., Weiser, R., Floto, R. A., Davies, J. C., Fothergill, J. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Selection+of+relevant+bacterial+strains+for+novel+therapeutic+testing%3A+a+Guidance+document+for+priority+cystic+fibrosis+lung+pathogens%5BTitle%5D)+AND+%22Curr+Clin+MicrobiolRep%22%5BJournal%5D)">Selection of relevant bacterial strains for novel therapeutic testing: a Guidance document for priority cystic fibrosis lung pathogens.</a> Curr Clin MicrobiolRep. 9 (4), 33-45 (2022).</li>
<li>Carter, M. E. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+subtype+of+a+Pseudomonas+aeruginosa+cystic+fibrosis+epidemic+strain+exhibits+enhanced+virulence+in+a+murine+model+of+acute+respiratory+infection%5BTitle%5D)+AND+%22J+Infect+Dis%22%5BJournal%5D)">A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection.</a> J Infect Dis. 202 (6), 935-942 (2010).</li>
<li>Herrmann, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Colistin-tobramycin+combinations+are+superior+to+monotherapy+concerning+the+killing+of+biofilm+Pseudomonas+aeruginosa%5BTitle%5D)+AND+%22J+Infect+Dis%22%5BJournal%5D)">Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.</a> J Infect Dis. 202 (10), 1585-1592 (2010).</li>
<li>Hennig, S., Standing, J. F., Staatz, C. E., Thomson, A. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Population+pharmacokinetics+of+tobramycin+in+patients+with+and+without+cystic+fibrosis%5BTitle%5D)+AND+%22Clin+Pharmacokinet%22%5BJournal%5D)">Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.</a> Clin Pharmacokinet. 52 (4), 289-301 (2013).</li>
<li>Reyhanoglu, G., Reddivari, A. K. R. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aReyhanoglu%2C+G+%22Tobramycin%22">Tobramycin</a>. , StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551695/ (2023).</li>
<li>Crass, R. L., Rutter, W. C., Burgess, D. R., Martin, C. A., Burgess, D. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nephrotoxicity+in+patients+with+or+without+cystic+fibrosis+treated+with+polymyxin+b+compared+to+colistin%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin b compared to colistin.</a> Antimicrob Agents Chemother. 61 (4), e02329-e02416 (2017).</li>
<li>Deacon, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antimicrobial+efficacy+of+tobramycin+polymeric+nanoparticles+for+Pseudomonas+aeruginosa+infections+in+cystic+fibrosis%3A+Formulation%2C+characterization+and+functionalization+with+dornase+alfa+%28DNase%29%5BTitle%5D)+AND+%22J+Control+Release%22%5BJournal%5D)">Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterization and functionalization with dornase alfa (DNase).</a> J Control Release. 198, 55-61 (2015).</li>
<li>Tamma, P. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Infectious+Diseases+Society+of+America+2022+guidance+on+the+treatment+of+extended-spectrum+%CE%B2-lactamase+producing+enterobacterales+%28ESBL-E%29%2C+carbapenem-resistant+enterobacterales+%28CRE%29%2C+and+Pseudomonas+aeruginosa+with+difficult-to-treat+resistance+%28DTR-P.+aeruginosa%29%5BTitle%5D)+AND+%22Clin+Infect+Dis%22%5BJournal%5D)">Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).</a> Clin Infect Dis. 75 (2), 187-212 (2022).</li>
<li>Charan, J., Kantharia, N. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((How+to+calculate+sample+size+in+animal+studies%5BTitle%5D)+AND+%22J+PharmacolPharmacother%22%5BJournal%5D)">How to calculate sample size in animal studies.</a> J PharmacolPharmacother. 4 (4), 303-306 (2022).</li>
<li>Murray, C. J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Global+burden+of+bacterial+antimicrobial+resistance+in+2019%3A+A+systematic+analysis%5BTitle%5D)+AND+%22Lancet%22%5BJournal%5D)">Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis.</a> Lancet. 399 (10325), 629-655 (2022).</li>
<li>de Kraker, M. E. A., Stewardson, A. J., Harbarth, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Will+10+million+people+die+a+year+due+to+antimicrobial+resistance+by+2050%5BTitle%5D)+AND+%22PLoS+Med%22%5BJournal%5D)">Will 10 million people die a year due to antimicrobial resistance by 2050.</a> PLoS Med. 13 (11), e1002184(2016).</li>
<li>Prasad, N. K., Seiple, I. B., Cirz, R. T., Rosenberg, O. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Leaks+in+the+pipeline%3A+A+failure+analysis+of+gram-negative+antibiotic+development+from+2010+to+2020%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Leaks in the pipeline: A failure analysis of gram-negative antibiotic development from 2010 to 2020.</a> Antimicrob Agents Chemother. 66 (5), e0005422(2022).</li>
<li>Wang, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+novel+Galleria+mellonella+experimental+model+for+zoonotic+pathogen+Brucella%5BTitle%5D)+AND+%22Virulence%22%5BJournal%5D)">A novel Galleria mellonella experimental model for zoonotic pathogen Brucella.</a> Virulence. 14 (1), 2268496(2023).</li>
<li>Senior, N. J., Titball, R. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation+and+primary+culture+of+Galleria+mellonella+hemocytes+for+infection+studies%5BTitle%5D)+AND+%22F1000Res%22%5BJournal%5D)">Isolation and primary culture of Galleria mellonella hemocytes for infection studies.</a> F1000Res. 9, 1932(2021).</li>
</ol>

<table><tbody><tr><td>22sゲージ、小型ハブRNニードル、2インチ、ポイントスタイル2</td><td>ハミルトン</td><td>7758-03</td><td>ハミルトン注射器の交換品です。</td></tr><tr><td>細菌感染ストック</td><td></td><td></td><td>既知の密度(CFU/mL)を持つ細菌在庫が成長の中間指数段階で凍結されている場合、</td></tr><tr><td>エタノール</td><td>フィッシャー・サイエンティフィック</td><td>10610813</td><td>他のメーカーが使われることもあります。</td></tr><tr><td>G. mellonella 幼虫</td><td>ライブフード</td><td>5.06045E+12</td><td>このサプライヤーの注文は「「研究室用の新しいストック」2024年4月現在、新品は月曜日にサプライヤーに納品されます。注文はその時に行い、水曜日の配達予定です。</td></tr><tr><td>マイクロリットル注射器</td><td>ハミルトン</td><td>80630</td><td>80630シリンジには100とマイクロがあります。Lの容量です。他にも80430、80530、80730などの巻物が存在します。</td></tr><tr><td>ペトリ皿</td><td>フィッシャー・サイエンティフィック</td><td>12674785</td><td>他のメーカーが使われることもあります。</td></tr></tbody></table>

抗菌スクリーニングモデルとしてのgalleria mellonella

Galleria mellonella as an Antimicrobial Screening Model

抗菌スクリーニングモデルとしてのGalleria mellonella

To combat the rising global issue of antibiotic resistance, the accelerated development of novel antibiotics is essential. Current preclinical ...

galleria-mellonella-as-an-antimicrobial-screening-model

Research

JoVE Journal

Biology

生物学

大きいワックス蛾の幼虫の経口およびイントラhaemocolic感染...

昆虫<em&gt;ハチノスツヅリガ</em&gt;細菌性病因を調査するための強力な感染モデルとして

ワックス蛾ハチノスツヅリガの幼虫は、最近、 レジオネラ·ニューモフィラ感染を研究するためのin vivoモデルとして設立されました。ここでは、接種、細菌の病原性とレプリケーションの測定だけでなく、感染した血球の抽出と分析を含む幼虫にレジオネラ症の病因を特徴づける基本的な技術を実証する。...

使用<em&gt;ハチノスツヅリガ</em&gt;モデル生物として研究する<em&gt;レジオネラ·ニューモフィラ</em&gt;感染症

ハチミツガは播種性カンジダ症の無脊椎動物モデルとして機能します。ここで、感染は詳細プロトコルし、モデルの有効性のサポート...

播種性カンジダ症のハチミツガWaxworm 感染症モデル

ここでは、我々 はハチミツガの幼虫を用いた経口投与モデルの詳細なプロトコルを提供し、特徴付ける方法による自然免疫応答。このプロトコルを使用して、実用的な経験のない研究者はg.

ハチミツガ口腔管理モデル Study Commensal-Induced 自然免疫応答

ガレリアメロネラは最近、結核複合体の再現性、安価、倫理的に許容可能な感染モデルとして設立されました。ここでは、生物発光マイコバクテリウム・ボビスBCGルクスを用いたG.メロネラの正常な感染を確立するためのステップを説明し、実証する。...

結核複合体を研究するための感染モデルとしての無脊椎動物ガレリアメロネラの使用

全体プラスミドの部位特異的突然変異誘発は、元のプラスミドのわずかに異なるバリエーションを作成する簡単な方法です。ここでは、プラスミドを使用して、標準試薬に塩基置換を導入しやすいと費用対効果の高い方法を示しています。...

全プラスミドの自家製のサイトが特異的突然変異誘発

このビデオでは、草食性に宿主植物の抵抗性のメカニズムを説明し、のアワフキムシ抵抗に抗生作用と耐性の相対的な寄与を推定するのない選択式テストを示しています...

特徴付ける草食動物の耐性機構：上Spittlebugs Brachiaria属。例として

成人臍orangeworm（の電気生理学的応答の測定による急速に画面宿主植物揮発性物質の方法...

宿主植物の揮発性物質のスクリーニングツールとしてElectroantennographicバイオアッセイ

&gt;jove_content&lt;この論文では、トリパノソーマチド病原体におけるRNA編集のユニークなプロセスを標的とする化学物質のハイスループットスクリーニングに適用可能な、高感度のリボザイムベースのアッセイについて説明しています。阻害剤は、RNA編集プロセスの仮説駆動型解析のツールとして、また最終的には治療薬として使用することができます。...

トリパノソーマにおけるRNA編集に対する薬剤をスクリーニングするためのレポーターとして、RNA触媒

ここでは、細胞ベースのレポーター遺伝子アッセイを、3'...

転写後調節される遺伝子の化学モジュレーターのためのハイスループットスクリーニング

学ぶGalleria mellonella感染モデルを用いた前臨床抗菌薬評価の標準化手法。トブラマイシンの最適用量と治療タイミングによる生存率向上を検証し、慢性呼吸器感染症治療薬開発の信頼性向上に貢献する。

抗菌スクリーニングモデルとしてのGalleria mellonella

さらに動画を探す